Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay

G Matulis; P Jüni; P M Villiger; S D Gadola

doi:10.1136/ard.2007.070789

Responses

Extended report

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

The theoretical advantages of the ELISPOT assay based T-SPOT.TB test
San San Aye
Published on: 13 April 2016
PHA concentration in IGRA assays
Christopher J Granger
Published on: 13 April 2016

Published on: 13 April 2016
The theoretical advantages of the ELISPOT assay based T-SPOT.TB test
- San San Aye, Research Co-ordinator
Dear Editor,
After carefully reading this article and other related references, weagree that detection of M tuberculosis using interferon gamma release assays (IGRA) is more sensitive and specific than the classic Tuberculin Skin Test (TST) for the detection of Latent TB Infection (LTBI) in patients receiving immunosuppressive therapy. As the authors indicate, there are two commercially available IGRAs, an Enzyme Link...
Show More

Dear Editor,
After carefully reading this article and other related references, weagree that detection of M tuberculosis using interferon gamma release assays (IGRA) is more sensitive and specific than the classic Tuberculin Skin Test (TST) for the detection of Latent TB Infection (LTBI) in patients receiving immunosuppressive therapy. As the authors indicate, there are two commercially available IGRAs, an Enzyme Linked Immunosorbent Assay (ELISA), QuantiFeron TB-Gold, and an Enzyme Linked Immunospot (ELISPOT) assay, T-SPOT.TB.
It has been shown that the ELISPOT methodology can be up to 200 times more sensitive than ELISA. T-SPOT.TB requires just a few spots to give a positive result (one spot = one effector T cell), so just a few activated T cells in a sample can provide a positive result. Many more T cells are required to provide a measurable change in cytokine concentration by ELISA.
In addition to the methodological advantages of ELISPOT over ELISA, the T-SPOT.TB protocol has some procedural differences that produce a more reliable result. T-SPOT.TB has a washing step that removes the source of interfering background signals, which reduces sensitivity and produces indeterminate results. This washing step is absent in the ELISA based QuantiFeron TB-Gold.
In the T-SPOT.TB procedure, the Peripheral Blood Mononuclear Cells (PBMCs) are counted. This step ensures there are an adequate number of cells and that each time the assay is performed there is the same number of cells present, which standardizes the assay. This step maintains the high sensitivity in immunocompromised and immunosuppressed patients. This step is also absent in the ELISA based QuantiFeron TB-Gold.
In conclusion, we believe that T-SPOT.TB is a novel in vitro diagnostic test that uniquely identifies the number of T cells specific to Mycobacterium tuberculosis antigens and therefore is better equipped to identify LTBI, particularly in immunosuppressed populations.
References
1. Tanguay and Killion. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine and Cytokine Research 1994;13:259–263.
2. G Matulis, P Jüni, P M Villiger, S D Gadola. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon assay. Ann Rheum Dis 2008;67:84-90.
3. www.oxfordimmunotec.com
4. www.cellestis.com
Show Less

Conflict of Interest:
None declared.
- Back to top
Published on: 13 April 2016
PHA concentration in IGRA assays
- Christopher J Granger, Director, Professional Relations
Dear Editor, In the article by Matulis et al, published online on 20 July 2007 the authors state in their discussion that “Compared with the ELISA test used in our study the IFN-gamma ELISPOT test was previously reported to have lower rates of indeterminate results (1). These differences may, among other reasons, be explained by differences in the concentrations of the mitogen PHA between the two test systems”. Can the authors...
Show More

Dear Editor, In the article by Matulis et al, published online on 20 July 2007 the authors state in their discussion that “Compared with the ELISA test used in our study the IFN-gamma ELISPOT test was previously reported to have lower rates of indeterminate results (1). These differences may, among other reasons, be explained by differences in the concentrations of the mitogen PHA between the two test systems”. Can the authors please provide the PHA concentrations used in the QuantiFERON-TB Gold and IFN-gamma ELISPOT (T-SPOT.TB) assays and explain if they are indeed different.
We agree with the authors statement “the elevation of PHA concentrations to lower the rates of indeterminate results will not per se lead to a more accurate test: T-lymphocytes may respond to the strong unspecific stimulus, but not to tuberculosis specific peptides”. The authors continue “the performance of IFN gamma assays using higher PHA concentrations in the positive control reaction of the test may therefore be overestimated.” The authors are suggesting that an assay system that elevates PHA concentrations will have lower indeterminate rates. However, this would also allow the assay to report results in individuals who may not respond to tuberculosis-specific peptides. In some cases these subjects will be falsely negative. Therefore, following the author’s logic, an assay system where the PHA concentration has been increased to lower the numbers of indeterminates would result in lower sensitivity.
The authors imply that the IFN-ELISPOT assay system (T-SPOT.TB) has been modified in this way, which would explain the previously reported lower rates of indeterminate results compared to the IFN-ELISA system (QuantiFERON TB Gold). However, if this were the case, the lower indeterminate rates associated with the T-SPOT.TB system would also result in a reduced ability to identify infected subjects (lower sensitivity). However, previous studies have shown that T-SPOT.TB has BOTH lower indeterminates AND higher sensitivity than QFN-Gold1 (1,2,3).
This is consistent with the fact that the ELISPOT assay methodology is orders of magnitude more sensitive than the ELISA methodology (4,5,6) in detecting antigen-specific T cell response.
In conclusion, indeterminate results should be reviewed along with the sensitivity of a particular assay system since increasing the PHA concentration in order to reduce the rate of indeterminate results will directly decrease the sensitivity of that assay.
References
1. Ferrara G, Losi M, D’Amico R, Roversi P, Piro, Meacci M, Meccugni B, Marchetti Dori I, Andreani A, Bergamini B, Mussini C, Rumpianesi F, Fabbri L, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328–34.
2. Lee JY, Choi HJ, Park I-N, Hong S-B, Oh Y-M, Lim C-M, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, and Shim TS. Comparison of two commercial interferon-ã assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24–30.
3. Goletti D, Carrara D, Vincenti D, Saltini D, Busi Rizzi E, Schinina V, Ippolito G, Amicosante M and Girardi E. Accuracy of an immunediagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 2006 10.1111/j.1469-0691.
4. Tanguay S, Killion JJ. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res 1994;13(4):259-63.
5. Tassignon J, Burny W, Dahmani S, Zhou L, Stordeur P, Byl B, De Groote D. Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. 1. J Immunol Methods 2005;305(2):188-98. Epub 2005 Aug 31.
6. Ekerfelt C. Ernerudh J. Jenmalm MC. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J Immunol Methods 2002;260(1-2):55-67.
Chris Granger is an employee of Oxford Immunotec, the manufacturer of T-SPOT.TB.
Show Less

Conflict of Interest:
None declared.
- Back to top

Main menu

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Read the full text or download the PDF:

Log in using your username and password